新股暗盤 | 榮昌生物-B(9995.HK)暗盤段漲近10%
格隆匯11月6日丨據輝立證券,榮昌生物-B(9995.HK)暗盤段現報57.2港元,較發行價52.1港元漲9.78%。公司是一家正在進入商業化階段的生物製藥公司,預計將於2020年第四季度及2021年第二季度分別獲得中國藥監局批准後,在中國市場商業化推廣泰它西普用於治療系統性紅斑狼瘡(SLE)及disitamab vedotin用於治療胃癌(GC)。此次上市將全球發售7653.7萬股,其中香港發售3061.5萬股,國際發售4592.2萬股,每手500股,一手中籤率90%,香港公開發售獲53.43倍認購,淨籌37.766億港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.